resistanceBio, Inc.

Using AI to predict and block oncological drug resistance

Split-off from Viosera Therapeutics, Inc. in October 2021 by founder Chris Bulow and Nick Golder to develop therapies that overcome cancer-drug resistance. The company has developed the ResCue System that enables assessment of the mechanisms by which cancer cells evolve and mutate to evade drug treatment. By assessing the process through time, the system is able to identify additional drug targets thereby suggesting orthogonal combinatory treatment regimes that can provide durable cures.